Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02141308
Other study ID # IRB00010511
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 2014
Est. completion date December 2026

Study information

Verified date February 2024
Source Oregon Health and Science University
Contact Kevin Lathrop
Phone 503-494-8024
Email lathropk@ohsu.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels. The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.


Description:

Optical coherence tomography (OCT) is an imaging technology that can perform non-contact cross-sectional imaging of retinal and choroidal tissue structure in real time by measuring the intensity of reflected light. Tomographic images are generated by scanning the optical probe beam across the tissue structure of interest. OCT has become one of the most widely used imaging technologies by ophthalmologists. Its advantages include being a non-contact imaging modality, having micron-level resolution, producing a digital image that can be viewed electronically, and providing a reproducible quantitative measurement. New functional OCT including Doppler OCT and OCT angiography may allow an assessment of retinal blood flow and do away with the need for the more invasive fluorescein angiography (FA) test. Thus, if the diagnostic data provided by functional OCT are at least equivalent or superior to those achieved by FA, patients and healthcare providers could realize a substantial benefit in utilizing this technology in the evaluation of retinal vascular disease. Even in the scenario in which an FA is not usually clinically indicated, OCT angiography may provide information over that of standard OCT and clinical examination and history, that might help clinicians better understand the etiology of the disease, and may even help inform treatment response.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 7 Years to 100 Years
Eligibility Subject-Level Criteria: Inclusion a. Diagnosis of retinal or choroidal disease Exclusion 1. Inability to give informed consent. 2. Inability to complete study tests within a 30 day period 3. Significant renal disease, defined as a history of chornic renal failure requiring dialysis or kidney transplant. 4. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control). 5. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible. 6. Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography. Study-Eye Criteria: Inclusion a. Diagnosis of retinal or choroidal disease Exclusion 1. Inability to maintain stable fixation for OCT imaging. 2. An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract) 3. Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or worse if the eye was otherwise normal). 4. Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner.

Study Design


Locations

Country Name City State
United States Casey Eye Institute, Oregon Health & Science University Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Retinal and Choroidal Blood Flow Determination whether disease affecting the retina and/or choroid shows a change in blood flow that differs from healthy eyes. Total retinal/choroidal blood flow will be measured in uL/min. One year
See also
  Status Clinical Trial Phase
Completed NCT03497000 - Effects of OCTA-guided PDT in Acute CSC N/A
Recruiting NCT03692169 - The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
Not yet recruiting NCT02215330 - A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Phase 2/Phase 3
Completed NCT01990677 - Eplerenone for the Treatment of Central Serous Chorioretinopathy N/A
Completed NCT01971190 - Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Phase 2
Active, not recruiting NCT01710332 - The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Phase 2
Active, not recruiting NCT00403884 - Selective RPE Laser Treatment (SRT) for Various Macular Diseases N/A
Recruiting NCT05570591 - Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy N/A
Recruiting NCT05589974 - Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
Completed NCT05104138 - Eplerenone Versus PDT: Comparative Study by OCTA
Completed NCT01880788 - Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD N/A
Terminated NCT01982383 - Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy N/A
Completed NCT01327170 - Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy N/A
Completed NCT01019668 - Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy N/A
Recruiting NCT06346405 - Central Serous Chorioretinopathy and Micropulse Laser Treatment
Completed NCT01822561 - Eplerenone for Central Serous Chorioretinopathy Phase 2
Completed NCT00802906 - Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) N/A
Withdrawn NCT05679180 - Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE N/A
Completed NCT05686421 - Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations N/A
Completed NCT03758963 - Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy N/A